Neurology

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses,...

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- The FDA Division of Neurology provided positive feedback supporting a regulatory pathway...

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc

Custom Health Announces Binding Letter of Intent to Acquire Evergreen Pharmacy; Expected to Add Over US$78 Million in Annual Revenue

Custom Health has entered into a binding letter of intent (the "LOI") to acquire Evergreen Pharmacy LLC ("Evergreen"), a Wisconsin-based...

CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development

Consortium initially brings together Lunit, Mindpeak, Imagene AI, Dipath AI, Nucleai, Tivenix and Indica Labs to give biopharma sponsors a...

BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism

Fully non-hallucinogenic, oral, non-scheduled 5-HT2A neuroplastogen differentiates BETR-001 from every other 5-HT2A agonist program; depression and other psychiatric disorders retained...

Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine.

Dysport® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraineDysport is...

error: Content is protected !!